The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
Abstract
Objective: To investigate the effect of infliximab treatment on antinuclear antibodies (ANAs), anti–double‐stranded DNA (anti‐dsDNA), antinucleosome, antihistone, and anti–extractable nuclear antigen (anti‐ENA) antibodies in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients. Methods: Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp‐2 cells. Anti‐dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme‐linked immunosorbent assay (ELISA) and were further isotyped with γ, μ, and α chain–specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Antihistone and anti‐ENA antibodies were detected by line immunoassay. Results: Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti‐dsDNA antibodies. After infliximab treatment, 7 RA patients (P = 0.016) and 6 SpA patients (P = 0.031) became positive for anti‐dsDNA antibodies. All 7 anti‐dsDNA–positive RA patients had IgM and IgA anti‐dsDNA antibodies. Three of the 6 anti‐dsDNA–positive SpA patients had IgM and IgA anti‐dsDNA antibodies, and 2 had IgM anti‐dsDNA antibodies alone. In both diseases, the IgM anti‐dsDNA antibodies appeared before the IgA anti‐dsDNA antibodies. During the observation period, no IgG anti‐dsDNA antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti‐ENA antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant. Conclusion: Infliximab treatment may induce ANAs, and especially IgM and IgA anti‐dsDNA antibodies, in RA and SpA patients. However, no anti‐dsDNA IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti‐ENA antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 437
Ledingham, J., Deighton, C., & on behalf of the British Society for Rheumatology Standards, G. A. A. W. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh464 · Cited by 331
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Suhler, E. B. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.903 · Cited by 306
Metadata
- Authors
- De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 48
- Issue
- 4
- Pages
- 1015-1023
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2168626353
- Cited by
- 223
- References
- 2
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. https://app.cochat.ai/papers/10.1002/art.10876
- The paper
- De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F. (2003). Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis & Rheumatism. https://doi.org/10.1002/art.10876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.